Date
Title
Oct 29, 2020

Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

Oct 19, 2020

Innocoll to Partner with Mallinckrodt Acute Care Sales Team to Support the Launch of XARACOLL® (bupivacaine HCl) implant

Aug 31, 2020

FDA Approves XARACOLL® (bupivacaine HCl) Implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

Mar 26, 2020

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL® for the Management of Postsurgical Pain

Feb 27, 2020

Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL® for the Management of Postsurgical Pain after Open Inguinal Hernia Surgery

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.

© 2020-2004 Innocoll. All rights reserved.
All Trademarks are owned by Innocoll Pharmaceuticals Limited